



**FINAL REPORT**

**Dates:** September 14-17, 2022

**Venue:** Hyatt Regency Jersey City on the Hudson, Jersey City, New Jersey, USA

**Website:** [2022 InSiGHT biennial meeting 14-17 Sept 2022 Jersey City / New York City, USA - InSiGHT \(insight-group.org\)](https://insight-group.org)

**Registration Fees:**

Category	Early Bird	Regular	On-Site
Professional Member	\$900	\$1050	\$1250
Professional Non-Member	\$1100	\$1250	\$1450
Member Nurses/Genetic Counselor/Trainees	\$550	\$650	\$750
Non-Member Nurses/Genetic Counselor/Trainees	\$675	\$775	\$875
Daily Registration	--	\$450	\$520

**Attendance:**

Total Registrations: 220

Member Professional Degree Holders (MD, PhD): 87

Member Nurses, Genetic Councilors, Students/Trainees: 23

Non-Member Professional Degree Holders (MD, PhD): 44

Non-Member Nurses, Genetic Councilors, Students/Trainees: 45

Daily Registrations and Guests: 21



**Abstracts Submitted:** 137

**Scientific Program:** (full program listed below)

Research podium presentations: 68

Research Poster Presentations: 57

Named Lectures: 5

Invited Talks/Presentations: 34

Panel Discussions: 5



**Supported Guests:** InSiGHT provided grant support to allow attendees from under-represented countries to attend and participate in the meeting. The 2 attendees that were supported were:

Dr. Luis Lobato, Brazil

Dr. Achille Manirakiza, Rwanda

**CME/CEUs:** Provided by The Ohio State University

**Social and Networking Events:**

Welcome Reception- boat cruise on the Hudson River

Poster Reception

Gala Dinner in Hyatt Ballroom overlooking the Hudson River



Full Scientific Program:

<p align="center"><b>9th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT 2022)</b>  <b>Scientific Program</b>  <b>Jersey City, NJ, USA, 14 - 17 September 2022</b></p>		
START	END	Wednesday, September 14, 2022
13:00	13:15	Welcome and Announcements <i>Matthew Kalady, MD</i>
13:15	14:00	Session 1: Lynch Syndrome
13:15	13:30	Introduction Tribute to Henry Lynch/ Introduction to Henry Lynch Lecture <i>Richard Boland, MD</i>
13:30	14:00	Henry Lynch Lecture: Lynch Syndrome Vaccines <i>Steven M. Lipkin, MD, PhD</i>
14:00	15:30	Abstracts Presentations 1 <i>Moderators: Matthew Kalady, MD; Brandie Leach, MS, LGC</i>  The immune profile of normal colonic mucosa as a possible tumor risk modifier in Lynch syndrome, <i>Lena Bohaumilitzky, Germany</i> Molecular carcinogenesis pathway of MLH1-associated Lynch syndrome colorectal cancer unraveled: "two-in-one hit" model, <i>Aysel Ahadova, Germany</i> Mutation rate evolution drives immune escape in mismatch repair-deficient cancer, <i>Marnix Jansen, United Kingdom</i> Co-evolution of mismatch repair loss and the immune response in Lynch Syndrome, <i>Ottillie D Swinyard, United Kingdom</i> Lynch syndrome-associated epithelial ovarian cancer and its immunological profile, <i>Maria Rasmussen, Denmark</i> Immunogenicity and HLA binding affinity of Lynch Syndrome associated frameshift peptide neoantigens, <i>Alejandro Hernandez Sanchez, Germany</i> The INDICATE initiative: Is HLA Type a modulator of tumor risk in Lynch syndrome? <i>Matthias Kloor, Germany</i> MSI-H and MSI-L mark opposite ends of the tetranucleotide repeat instability phenotype spectrum, <i>Maija R J Kohonen Corish, Australia</i> Genome-wide DNA methylation and somatic mutational landscape resolve the molecular causality of MLH1-deficient colorectal cancer and designate MLH1 epimutation carriers, <i>Jihoon E Joo, Australia</i> An evaluation of RMH Diagnostic pathways for CRC testing considering the introduction of the NHS National Genomic Test Directory and the potential benefit of immunotherapy in a subset of MMR-d, MSI CRC patients, <i>Andrew George, United Kingdom</i>
15:30	15:45	Invited Lecture Non-Polyp Routes to Cancer  <i>Magnus von Knebel Doeberitz, MD</i>
15:45	16:15	BREAK
16:15	16:45	Session 2: Global Issues

16:15	16:45	Global Issues in Hereditary GI Cancer Syndromes Panel <i>Moderator: James Church, MD</i> <i>Panelists: Luiz Lobato, MD, PhD; Swati Patel, MD; Joanne Ngeow, MD; Susan Parry, MD, PhD; Nasser Alsanea, MD; Achille Manirakiza, MD</i>
16:45	17:15	Adjournment
17:15		Welcome reception
START	END	Thursday, September 15, 2022
8:00	8:40	Session 3: Polyposis
8:00	8:10	Session dedicated to Dennis Ahnen <i>Swati Patel, MD</i>
8:10	8:15	Introduction to Sir Ian Todd Lecture <i>Laura Valle, MD, PhD</i>
8:15	8:40	Sir Ian Todd Lecture: 30 years after the discovery of APC <i>Stefan Aretz, MD, PhD</i>
8:40	9:45	Abstracts Presentations 2 <i>Moderators: Ann-Sofie Backman, MD; Patrick Lynch, MD</i>  Patient-derived 3D-Spheroid Cultures: A Novel Approach to in vitro Study of Familial Adenomatous Polyposis, <i>Alicia Adams, United States</i> Pyrvinium Inhibits Familial Adenomatous Polyposis Patient-derived 3D Adenoma Organoids, <i>Rami James Aoun, United States</i> {APC} mosaicism is a relevant explanation in (mild) polyposis phenotypes and testing reveals interesting cases such as >1 mosaic cases in a family, <i>Diantha Terlouw, Netherlands</i> Microbiome Profiling in Patients with Adenomatous Polyposis Compared to sporadic Subjects, <i>Revital Kariv, Israel</i> Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study, <i>Patrizia Pasanisi, Italy</i> The opinions of adolescents and young people with familial adenomatous polyposis about timing of surgery: a service evaluation, <i>Jacqueline M Hawkins, United Kingdom</i> Superior Rectal Artery sparing in total colectomies with ileorectal anastomosis to reduce anastomotic leakage in patients with Familial Polyposis, <i>Marco Vitellaro, Italy</i> Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study, <i>Marco Vitellaro, Italy</i>
9:45	10:00	Gastric Cancer in FAP <i>Sonia Kupfer, MD</i>
10:00	10:15	Problematic Polyposes <i>Bryson Katona, MD, PhD</i>
10:15	10:45	BREAK
10:45	11:30	Session 4: Polyposis Management

10:45	11:30	<p>Panel</p> <p>Clinical Management of Polyposis (timing surgery of FAP/AFAP/MAP; management of pouch and ATZ; management of rectal polyps after IRA; management of gastric and duodenal polyps)</p> <p><i>Moderator: Susan Parry, MD, PhD; Jose Guillem, MD</i></p> <p><i>Speaker and Panelist: David Liska, MD; Paul Wise, MD; Fay Kastrinos, MD, MPH; Ann-Sofie Backman, MD</i></p>
11:30	12:15	<p>Abstracts Presentations 3</p> <p><i>Moderators: Aimee Lucas, MD; Allan Spigelman, MD</i></p> <p>Evaluation of novel approaches to support variant classification in DNA mismatch repair genes, <i>Romy Walker, Australia</i></p> <p>A fully calibrated and validated {in vitro} functional assay for the diagnosis of Variants of Uncertain Significance in Lynch syndrome, <i>Emily Rayner, Netherlands</i></p> <p>Providing More Answers for Patients with Supplemental RNA Analysis of Colorectal Cancer Associated Genes, <i>Daniel E Pineda Alvarez, United States</i></p> <p>Mismatch Repair variant classification with ACMG/AMP criteria and comparison with Bayesian probability framework, <i>Finlay Macrae, Australia</i></p> <p>{APC}-specific ACMG/AMP variant classification guideline alleviates the burden of variants of uncertain significance in ClinVar and locus-specific databases, <i>Stefan Aretz, Germany</i></p> <p>Clinically relevant combined effect of polygenic background, rare pathogenic germline variants, and family history on colorectal cancer incidence, <i>Stefan Aretz, Germany</i></p> <p>Assessment of the ability of the polygenic background to refine colorectal cancer risk in Lynch syndrome, <i>Joan Brunet, Spain</i></p>
12:15	13:40	LUNCH
13:40	14:15	Session 5: Extra Intestinal FAP
13:40	13:45	<p>Introduction to the Jagelman/ Church Lecture</p> <p><i>David Liska, MD</i></p>
13:45	14:15	<p>Named Lecture</p> <p>Jageman/ Church Lecture: Desmoid Tumours</p> <p><i>Matthew Kalady, MD</i></p>
14:15	15:00	<p>Abstracts Presentations 4</p> <p>Polyposis Plenary Abstracts</p> <p><i>Moderators: Susan Clark, MD, PhD; Finlay Macrae, MD, PhD</i></p> <p>Risk of malignant and benign thyroid disease in patients with familial adenomatous polyposis – a prospective surveillance study, <i>Robert Hüneburg, Germany</i></p> <p>Outcomes following duodenectomy in patients with familial adenomatous polyposis, <i>Isabel Martin, United Kingdom</i></p> <p>Development of ileal adenomas after ileal pouch-anal anastomosis versus end ileostomy in patients with familial adenomatous polyposis, <i>Arthur S. Aelvoet, Netherlands</i></p> <p>Defining the risk of desmoid disease in a high risk familial adenomatous polyposis (FAP) cohort, <i>Andrew Latchford, United Kingdom</i></p> <p>Intestinal Transplant for Desmoid Disease in FAP: A Single Institution Experience, <i>Nicholas Smith, United States</i></p>

15:00	15:45	Case Presentation Polyposis Case Presentation <i>Moderators: Sue Clark, MD; Finlay Macrae, MD, PhD</i> <i>Panelists: Mohammad Ali Abbass, MD; Lior Katz, MD; Gregory Idos, MD</i>
15:45	16:00	BREAK
16:00	16:30	Session 6: Other Polyposes
16:00	16:15	New CRC Polyposis Syndromes <i>Richarda De Voer, MD, PhD</i>
16:15	16:30	Serrated Polyposis: Updates and Management <i>Elena M. Stoffel, MD</i>
16:30	17:30	Abstracts Presentations 5 Non-FAP Polyposis Session and Abstracts <i>Moderators: Steven Erdman, MD; Brandie Leach, MS, LGC</i>  Characterizing POLE and POLD1 germline and somatic etiology in colorectal cancers demonstrating the defective DNA polymerase proofreading-related SBS10 tumour mutational signatures, <i>Khalid Mahmood, Australia</i> Identifying colorectal cancer caused by biallelic {MUTYH} pathogenic variants using tumor mutational signatures, <i>Peter Georgeson, Australia</i> Expanding the phenotype of NTHL1 tumor syndrome: results from a commercial laboratory, <i>Daniel E Pineda Alvarez, United States</i> Surveillance outcomes in Hereditary Mixed Polyposis Syndrome, <i>Sari Lieberman, Israel</i> Colorectal cancer risk and surveillance yield in patients with PTEN Hamartoma Tumour Syndrome (PHTS, Cowden syndrome), <i>Nicoline Hoogerbrugge, Netherlands</i> Results of in international survey of breast cancer in Peutz-Jeghers syndrome, <i>Andrew Latchford, United Kingdom</i>
17:30	17:45	ESPGHAN Working Groups on JPS <i>Carol A. Durno, MD</i>
17:45	18:00	Sirolimus in PTEN Study <i>Peter Stanich, MD</i>
18:00	18:30	Adjournment
18:30	19:30	Poster Reception with Authors
19:30	20:00	Adjournment
20:00		Council Dinner
START	END	Friday, September 16, 2022
8:00	8:25	Session 7: Lynch Syndrome
8:00	8:05	Introduction to Meera Khan Lecture <i>Aung Ko Win, PhD</i>

8:05	8:25	Meera Khan Lecture: Mutation based management of Lynch syndrome <i>Toni Seppala, MD, PhD</i>
8:25	9:20	Abstracts Presentations 6 <i>Moderators: Andrew Latchford, MD, PhD; Mev Dominguez-Valentin, PhD</i>  LynchRisk: a pedigree-based model for computing risks of Lynch syndrome and future cancer risks conditional on a family history of Lynch-associated cancers and clinical data, <i>Alexandra Lefebvre, France</i> Prevalence of Lynch syndrome in a multi-ethnic Asian population, <i>Joanne Ngeow, Singapore</i> Saturation-scale functional evidence supports clinical variant interpretation in Lynch Syndrome, <i>Anthony Scott, United States</i> Characterization of Blood-Derived Exosomal hTERT mRNA as a Biomarker for Colon Cancer and Lynch Syndrome, <i>Ido Laish, Israel</i> Cancer Prevention with Resistant Starch in Lynch syndrome patients in the CAPP2 Randomised Placebo Controlled Trial: planned 10-year follow-up, <i>John Burn, United Kingdom</i> Genomic responses to aspirin in colonic organoids from diverse individuals with and without Lynch syndrome, <i>Hina Usman, United States</i> Metachronous Colorectal Cancer Risk in Lynch syndrome: is Extensive Colectomy Necessary for all Carriers? <i>Ellis Eikenboom, Netherlands</i>
9:20	9:35	Update on CAPP3 <i>Sir John Burn, FRCP FRCPE FRCOG FRCPC FMedSci</i>
9:35	9:50	Immunotherapy <i>Leah Biller, MD</i>
9:50	10:15	BREAK
10:15	10:45	Session 8: Lynch Syndrome Testing
10:15	10:45	Debate Style Session: What's the best path to identify Lynch syndrome in CRC patients? Universal germline testing vs somatic testing vs MSI/IHC <i>Moderator: Sigurdis (Sisi) Haraldsdottir, MD</i> <i>Panelists: Heather Hampel, Zsofia Stadler, MD; Kevin Monahan, MD</i>
10:45	11:45	Abstracts Presentations 7 <i>Moderators: Nicoline Hoogerbrugge, MD, PhD; Michael Hall, MD</i>  10-year Results from Universal Mismatch-Repair (dMMR) Diagnostics in Colorectal Cancer; experiences from Denmark, <i>Jon Ambæk Durhuus, Denmark</i> Efficacy of routine microsatellite instability test in colorectal cancer for screening Lynch syndrome, <i>Hong-min Ahn, South Korea</i> Using Structured Family History Data in the Electronic Health Record to Identify Primary Care Patients Eligible for Genetic Testing for Hereditary Gastrointestinal and Other Cancer Syndromes, <i>Wendy Kohlmann, United States</i> Population-based study shows constitutional MLH1 methylation ("epimutation") underlies a significant fraction of incident mismatch repair-deficient, MLH1-hypermethylated colorectal cancer aged up to 55 years, but not endometrial cancer, <i>Megan P Hitchins, United States</i> DiagMMR, a novel carrier test validated for Lynch syndrome detection, <i>Minttu Kansikas, Finland</i>



		<p>A calibrated cell-based functional assay to aide classification of {MLH1} DNA mismatch repair gene variants, <i>Abhijit Rath, United States</i></p> <p>A collaborative multicenter approach for the classification of mismatch repair gene variants in Spain: results of a pilot study, <i>Marta Pineda, Spain</i></p>
11:45	12:15	<p>Lynch Syndrome Case Presentations: Colon &amp; Extra-colonic</p> <p><i>Moderators: TBD</i></p> <p><i>Panelists: Bryson Katona MD, Jill Genua, MD, Jewel Samadder, MD, TBD</i></p>
12:15	13:15	LUNCH
13:15	14:00	Session 9: Lynch Syndrome
13:15	14:00	<p>Debate style session:</p> <p>Screening intervals for Lynch syndrome</p> <p><i>Panelists: Pål Møller, MD, PhD; Carol Burke, MD</i></p>
14:00	15:00	<p>Abstracts Presentations 8</p> <p><i>Moderators: Allan Spigelman, MD, PhD; Evelien Dekker, MD, PhD</i></p> <p>Clinical description and first estimates of age-associated cancer risk and survival in the context of constitutional mismatch repair system deficiency (CMMRD syndrome): report from the European database of the European consortium C4CMMRD, <i>Chrystelle Colas, France</i></p> <p>The burden of microsatellite instability in the blood of constitutional mismatch repair deficiency syndrome is associated with patient genotype but not age of tumour onset, <i>Richard Gallon, United Kingdom</i></p> <p>Genetic Anticipation in MLH1-associated Lynch syndrome, <i>Arti Sharma Pandey, United States</i></p> <p>Endoscopic surveillance in Lynch syndrome, a prospective study of interval cancer and individual risk factors, <i>Nigin Jamizadeh, Sweden</i></p> <p>Real-time use of artificial intelligence in colorectal cancer surveillance of patients with Lynch syndrome – a randomized controlled trial, <i>Robert Hüneburg, Germany</i></p> <p>Risk-stratified FIT for urgent colonoscopy in Lynch Syndrome: A national clinical service throughout the COVID-19 pandemic, <i>Kevin Monahan, United Kingdom</i></p> <p>Fatalism and metaphor in Confucianism: a qualitative study of genetic testing barriers among FDRs of hereditary cancer patients from China, <i>Xiaodan Wu, China</i></p>
15:00	15:15	<p>CMMRD</p> <p><i>Uri Tabori, MD</i></p>
15:15	15:30	<p>Gene-Based Colorectal and Non-Colorectal Risk</p> <p><i>Aung Ko Win, PhD</i></p>
15:30	16:00	BREAK
16:00	16:45	Session 10: Early Onset Colorectal Cancer
16:00	16:10	<p>Tribute to Tom Weber</p> <p><i>Ms. Cindy Borassi</i></p>
16:10	16:25	<p>Summary from the EOCRC Summit</p> <p><i>Moderator: Cindy Borassi</i></p>
16:25	16:45	<p>EOCRC Clinical Features and Biomarkers</p> <p><i>Frank Sinicrope, MD</i></p>

16:45	17:15	<p>Abstracts Presentations 9 EOCRC Plenary Abstracts <i>Moderators: Gabriel Capella, MD, PhD; Laura Valle, MD, PhD</i></p> <p>Sex Disparities in Metabolic Transcriptomic Features Identify Novel Biomarkers of Early-Onset Colorectal Cancer, <i>Jose Perea, Spain</i> Risk factors associated with young onset advanced neoplasia at baseline and on follow up colonoscopy, <i>Carole Macaron, United States</i> Familial Component of Early-Onset Colorectal Cancer: An Opportunity for Prevention, <i>Francesc Balaguer, Spain</i></p>
17:15	18:00	<p>Business Meeting <i>Council; Matthew Kalady, MD; Susan Clark, MD, PhD</i></p>
18:00	19:00	Adjournment
19:00		Gala Event
START	END	Saturday, September 17, 2022
8:00	8:30	Session 11: Upper Gut Hereditary Cancer Syndromes
8:00	8:15	<p>Consortia updates in PDAC: CAPS &amp; PRECEDE <i>Randall E Brand, MD &amp; Diane Simeone, MD</i></p>
8:15	8:30	<p>Targeted therapies in PDAC <i>Kim Reiss-Binder, MD</i></p>
8:30	9:30	<p>Abstracts Presentations 10 <i>Moderators: Matt Yurgelun, MD; Susan Parry, MD, PhD</i></p> <p>Diagnostic Yield of Endoscopic Screening for Identification of Signet Ring Cell in Carriers of a Pathogenic Variant in CDH1: Single Center Experience, <i>Margaret Omalley, United States</i> Endoscopic diagnosis of early signet ring cell cancer in Hereditary diffuse Gastric Cancer Syndrome patients: a 16-year longitudinal prospective study, <i>Massimiliano Di Pietro, United Kingdom</i> First estimates of diffuse gastric cancer risks for carriers of {CTNNA1} germline pathogenic variants, <i>Chrystelle Colas, France</i> Outcomes of universal genetic testing in diverse pancreatic ductal adenocarcinoma patients, <i>Christine M Drogan, United States</i> Pancreatic Cancer Surveillance in {CDKN2A} Mutation Carriers: Yield and Outcomes of 20 Years Prospective Follow-up, <i>Monique Van Leerdam, Netherlands</i> Surveillance Outcome and Genetic Findings in Pancreatic Cancer High-Risk Population, <i>Guy Rosner, Israel</i></p>
9:30	9:45	<p>Updates on the Management of CDH1 <i>Parry Guilford, MD, PhD</i></p>

9:45	10:00	Introduction to Jeremy Jass Lecture <i>Michael Cruise, MD, PhD</i>
10:00	10:30	Jeremy Jass Lecture: Pathology of Hereditary Colorectal Cancer Syndromes <i>Wendy Frankel, MD</i>
10:30	11:00	BREAK
11:00	12:30	Session 12: Future of the Field
11:00	12:30	<p>Future of the Field <i>Moderators: Ian Frayling, MD, PhD; Sir John Burn FRCP FRCPE FRCOG FRCPCH FMedSci</i></p> <p>Taking action against risk modifiers of hereditary GI cancer syndromes <i>Daniel Buchanan, MD, PhD</i></p> <p>Expanding professional educational opportunities <i>Kathleen Blazer, PhD</i></p> <p>Approaches to population based screening for hereditary syndromes <i>William Foulkes, MD, PhD</i></p> <p>Artificial intelligence in endoscopy <i>Peter Stanich, MD</i></p> <p>Implementing genetic counselling extenders (chatbot) <i>Alanna Kulchak Rahm, PhD</i></p> <p>Top 5 Research Knowledge Gaps <i>Ian Frayling, MD</i></p>
12:30	12:45	Concluding Remarks <i>Matthew Kalady, MD</i>

**Sponsorship:**

<b>Sponsorship</b>	<b>Company</b>	<b>Amount(USD)</b>
Conference Bag & Notepads/Pens	Cleveland Clinic	USD 10.000,00
Silver Sponsor	The Janssen Oncology	USD 20.000,00
4 K for booth & 6 K grant	Myriad Genetics	USD 9.970,00
Silver Sponsor	Ohio State University	USD 20.000,00
Bag Insert	Conmed	USD 1.500,00
Awards	Familial Cancer	USD 483,00
<b>Sponsorship Total</b>	<b>Total</b>	<b>USD 61.953,00</b>
<b>Exhibition</b>	<b>Company</b>	<b>Amount</b>
Exhibit booth	LS CancerDiag	USD 5.000,00
Exhibit booth	Medtronic	USD 5.000,00
Exhibit booth	Immunovia, Inc.	USD 4.991,00
Exhibit booth	Oncolens	USD 3.000,00
Exhibit booth	Caris Life Sciences	USD 5.000,00
<b>Exhibition Total</b>		<b>USD 22.991,00</b>
<b>Grand Total</b>		<b>EUR 84.944,00</b>

## Final Budget:

InSIGHT 2022 Final Budget - November 16, 2022						
Item/Service	Details	Days	Quantity	Unit Rate (*)	Line Total	
<b>ESTIMATED INCOME</b>						
<b>1</b>	<b>Registration</b>			<b>65.34%</b>	<b>of Total Income</b>	
1 .1	InSIGHT Member - EARLY	1	67	USD 900.00	USD 60,291.00	
1 .2	InSIGHT Member - REGULAR	1	18	USD 1,050.00	USD 18,900.00	
1 .3	InSIGHT Member - ONSITE	1	2	USD 1,250.00	USD 2,500.00	
1 .4	Non-Member - EARLY	1	25	USD 1,100.00	USD 27,485.00	
1 .5	Non-Member - REGULAR	1	19	USD 1,250.00	USD 23,691.00	
1 .6	Non-Member - ONSITE	1	0	USD 1,450.00	USD 0.00	
1 .7	InSIGHT Member - Nurses, Genetic Counsellors, Stud	1	19	USD 550.00	USD 10,394.00	
1 .8	InSIGHT Member - Nurses, Genetic Counsellors, Stud	1	4	USD 650.00	USD 2,600.00	
1 .9	InSIGHT Member - Nurses, Genetic Counsellors, Stud	1	0	USD 750.00	USD 0.00	
1 .10	Non Member Nurses, Genetic Counsellors, Students/	1	35	USD 675.00	USD 23,612.00	
1 .11	Non Member Nurses, Genetic Counsellors, Students/	1	10	USD 775.00	USD 7,750.00	
1 .12	Non Member Nurses, Genetic Counsellors, Students/	1	0	USD 875.00	USD 0.00	
1 .13	Accompanying Person (access to Welcome Reception)	1	6	USD 100.00	USD 600.00	
1 .14	Accompanying Person (access to Friday Gala Event)	1	0	USD 125.00	USD 0.00	
1 .15	Daily Registration - EARLY	1	4	USD 390.00	USD 1,560.00	
1 .16	Daily Registration - REGULAR	1	11	USD 450.00	USD 4,950.00	
1 .17	Daily Registration - LATE	1	0	USD 520.00	USD 0.00	
			<b>220</b>		<b>USD 184,333.00</b>	
<b>2</b>	<b>Social Events</b>			<b>3.59%</b>	<b>of Total Income</b>	
2 .1	16 September 2022 - Friday - Gala Event - 5 Complimentary Tickets for Named Lecturers	1	81	USD 125.00	USD 10,125.00	
<b>Subtotal of Social Events</b>			<b>81</b>		<b>USD 10,125.00</b>	
<b>3</b>	<b>Complimentary Registrations</b>			<b>0.00%</b>	<b>of Total Income</b>	
3 .1	Invited Guests - Speakers - Committee	1	8	USD 0.00	USD 0.00	
3 .2	Exhibitor / Sponsor Registration	1	22	USD 0.00	USD 0.00	
<b>Subtotal of Complimentary Registrations</b>			<b>30</b>		<b>USD 0.00</b>	
<b>4</b>	<b>Sponsorship, Exhibition and Grants</b>			<b>31.07%</b>	<b>of Total Income</b>	
4 .1	Sponsorship, Exhibition and Grants	1	1	USD 84,943.99	USD 84,943.99	
4 .2	Meeting Lunch Service - Side Meetings	1	1	USD 2,267.11	USD 2,267.11	
4 .3	Certificates	1	1	USD 425.00	USD 425.00	
<b>Subtotal of Sponsorship, Exhibition and Grants</b>					<b>USD 87,636.10</b>	
<b>ESTIMATED INCOME TOTAL</b>					<b>USD 282,094.10</b>	

ESTIMATED EXPENSES					
<b>Congress Facility</b>				<b>0.00%</b>	<b>of Total Expenses</b>
.1	Congress Venue Rental	0	1	USD 0.00	USD 0.00
<b>Subtotal of Congress Facility</b>					<b>USD 0.00</b>
<b>Workshop Food and Beverage</b>				<b>40.29%</b>	<b>of Total Expenses</b>
.2	(Incl. Breakfasts, Gala Dinner, AM/PM Coffee Breaks	1	1	USD 154,320.18	USD 154,320.18
<b>Subtotal of Workshop Food and Beverage</b>					<b>USD 154,320.18</b>
<b>Audio Visual and IT</b>				<b>13.58%</b>	<b>of Total Expenses</b>
.1	AV equipment	1	1	USD 52,003.29	USD 52,003.29
.2	Wi-Fi	1	1	USD 0.00	USD 0.00
<b>Subtotal of Audio Visual and IT</b>					<b>USD 52,003.29</b>
<b>Marketing and Onsite Innovation</b>				<b>6.13%</b>	<b>of Total Expenses</b>
.1	Congress Logo and Graphic Theme	1	1	USD 2,500.00	USD 2,500.00
.2	Strategy, Marketing Timeline and Periodic Reporting	1	1	USD 4,000.00	USD 4,000.00
.3	E-mailing	1	1	USD 13,000.00	USD 13,000.00
.4	Social Media	1	1	USD 4,000.00	USD 4,000.00
<b>Subtotal of Marketing and Onsite Innovation</b>					<b>USD 23,500.00</b>
<b>Website &amp; Registration Portal</b>				<b>3.45%</b>	<b>of Total Expenses</b>
.1	Website	1	1	USD 2,200.00	USD 2,200.00
.2	Registration Portal	1	1	USD 4,500.00	USD 4,500.00
.3	Abstract Management Software	1	1	USD 3,000.00	USD 3,000.00
.4	Program App	1	1	USD 3,500.00	USD 3,500.00
<b>Subtotal of Website &amp; Registration Portal</b>					<b>USD 13,200.00</b>
<b>Faculty, Programme and Accreditation &amp; Awards</b>				<b>4.86%</b>	<b>of Total Expenses</b>
.1	Hotel - Named Lecturers	1	1	USD 7,741.21	USD 7,741.21
.2	CME and CEU Accreditation	1	1	USD 4,055.80	USD 4,055.80
.3	AWARDS - Best Podium and Best Poster Awards - 2 \$	1	2	USD 250.00	USD 500.00
.4	AWARDS - Name Lecture (4), and Presidential Award	1	1	USD 298.95	USD 298.95
.5	AWARDS - Exhibit Giveaway \$100 giftcard	1	1	USD 0.00	USD 0.00
.6	AWARDS - Honoraria	1	1	USD 0.00	USD 0.00
.7	AWARDS - Hotel Gifts for all faculty	1	1	USD 2,153.83	USD 2,153.83
.8	Council Dinner	1	1	USD 3,853.73	USD 3,853.73
<b>Subtotal of Faculty, Programme and Accreditation &amp; Awards</b>					<b>USD 18,603.52</b>
<b>Printed Materials</b>				<b>0.59%</b>	<b>of Total Expenses</b>
.1	Conference Bag	1	1	USD 981.04	USD 981.04
.2	Notepads and Mini Program	1	1	USD 602.36	USD 602.36
.3	Abstract E-Book	1	1	USD 0.00	USD 0.00
.4	Name tags with Plastic Holders	1	1	USD 441.33	USD 441.33
.5	Shipping	1	1	USD 243.32	USD 243.32
<b>Subtotal of Printed Materials</b>					<b>USD 2,268.05</b>
<b>Signage, Decor, Exhibition</b>				<b>0.69%</b>	<b>of Total Expenses</b>
.1	Signages ( Incl. Lectern & Headtable Visual for Main Hall)	1	1	USD 443.56	USD 443.56
.2	Poster Boards	1	1	USD 2,120.00	USD 2,120.00
.3	Lectern & Headtable Visual for Main Hall	1	0	USD 0.00	USD 0.00
.5	Registration Equipment	1	1	USD 73.57	USD 73.57
<b>Subtotal of Signage, Decor, Exhibition</b>					<b>USD 2,637.13</b>

<b>Social Programme</b>			<b>12.61%</b>	<b>of Total Expenses</b>	
Welcome Reception	1	1	USD 42,977.32	USD 42,977.32	
Welcome Reception Docking Fee	1	1	USD 1,343.48	USD 1,343.48	
Gala Dinner - Entertainment	1	1	USD 4,000.00	USD 4,000.00	
<b>Subtotal of Social Programme</b>				<b>USD 48,320.80</b>	
<b>Part-Time Staff</b>			<b>1.65%</b>	<b>of Total Expenses</b>	
Part-time staff	1	1	USD 6,305.69	USD 6,305.69	
Photographer	0	0	USD 0.00	USD 0.00	
<b>Subtotal of Part-Time Staff</b>				<b>USD 6,305.69</b>	
<b>PCO Services</b>			<b>10.86%</b>	<b>of Total Expenses</b>	
PCO Management Fee	<i>fix management fee</i>	1	1	USD 30,000.00	USD 30,000.00
Registration Handling Fee		1	220	USD 20.00	USD 4,400.00
Abstract Handling Fee	<i>will be revised according to the actual amount</i>	1	140	USD 20.00	USD 2,800.00
Sponsorship Sales and Operation		1	5.00%	USD 87,636.10	USD 4,381.81
<b>Subtotal of PCO Services</b>				<b>USD 41,581.81</b>	
<b>Miscellaneous</b>			<b>5.30%</b>	<b>of Total Expenses</b>	
Kenes Inspection Costs		1	1	USD 0.00	USD 0.00
Kenes Onsite Operation Costs		1	1	USD 17,262.09	USD 17,262.09
Banking Fees		1	1	USD 3,047.35	USD 3,047.35
Public Liability Insurance		0	1	USD 0.00	USD 0.00
<b>Subtotal of Miscellaneous</b>				<b>USD 20,309.44</b>	
<b>ESTIMATED EXPENSES TOTAL</b>				<b>USD 383,049.91</b>	
<b>ESTIMATED INCOME TOTAL</b>				<b>USD 282,094.10</b>	
<b>ESTIMATED EXPENSES TOTAL</b>				<b>USD 383,049.91</b>	
<b>ESTIMATED BUDGET PROFIT/DEFICIT</b>				<b>-USD 100,955.81</b>	